[Exploring protein degradation pathways as therapeutic innovations].

The disruption of proteostasis provides a favourable context for the emergence of therapeutic innovations, in particular by exploiting technologies such as the PROTAC (Proteolysis Targeting Chimera) approach. These technologies aim to selectively target proteins involved in various diseases, including cancer and neurodegenerative diseases, by inducing their specific degradation via the ubiquitin-proteasome system. The PROTAC approach opens new opportunities for restoring altered protein homeostasis and modulating the pathological consequences of proteostasis deregulation. In addition, by targeting proteins that are resistant to conventional therapeutic approaches, this new strategy offers a hope of treatment. By degrading target proteins, regardless of their structure or of mutations, the PROTAC approach opens the way to reaching previously inaccessible targets and reducing resistance to treatment.